Immunosuppression Associated With Novel Chemotherapy Agents and Monoclonal Antibodies

被引：50

作者：

Morrison, Vicki A. ^{[1
,2
]}

机构：

[1] Univ Minnesota, Minneapolis, MN 55417 USA

[2] VAMC, Minneapolis, MN 55417 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2014年 / 59卷

基金：

美国医疗保健研究与质量局;

关键词：

fludarabine; alemtuzumab; bortezomib; hepatitis B; tumor necrosis factor-alpha inhibitors; CHRONIC-LYMPHOCYTIC-LEUKEMIA; B-VIRUS REACTIVATION; RHEUMATOID-ARTHRITIS; SERIOUS INFECTIONS; CYTOMEGALOVIRUS REACTIVATION; 1ST-LINE THERAPY; TREATED PATIENTS; HERPES-ZOSTER; FLUDARABINE; ALEMTUZUMAB;

D O I：

10.1093/cid/ciu592

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The introduction of novel agents to the therapeutic armamentarium for oncologic, rheumatologic, and neurologic disorders has resulted in major clinical advances. These agents impact immune function, resulting in a discrete spectrum of infectious complications. Purine analogues and alemtuzumab alter cell-mediated immunity, resulting in opportunistic viral/fungal infections. Herpes zoster incidence increases with bortezomib. Hepatitis B reactivation may occur with rituximab. Cases of progressive multifocal leukoencephalopathy have occurred following monoclonal antibody therapy. Tumor necrosis factor-alpha inhibitor therapy is complicated by tuberculosis reactivation and fungal infections. We summarize the impact of these therapies on pathogenesis and spectrum of infection complicating their usage.

引用

页码：S360 / S364

页数：5

共 37 条

[1] Infections in patients with chronic lymphocytic leukemia treated with fludarabine [J].

Anaissie, EJ ;

Kontoyiannis, DP ;

O'Brien, S ;

Kantarjian, H ;

Robertson, L ;

Lerner, S ;

Keating, MJ .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) :559-566

[2] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[3] Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases [J].

Borchers, Andrea T. ;

Leibushor, Naama ;

Cheema, Gurtej S. ;

Naguwa, Stanley M. ;

Gershwin, M. Eric .

JOURNAL OF AUTOIMMUNITY, 2011, 37 (04) :273-288

[4] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[5] Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901 [J].

Byrd, John C. ;

Peterson, Bercedis L. ;

Rai, Kanti R. ;

Hurd, David ;

Hohl, Raymond ;

Perry, Michael C. ;

Gockerman, Jon ;

Nattam, Sreenivasa ;

Larson, Richard A. .

LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1589-1596

[6] Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study [J].

Chanan-Khan, Asher ;

Sonneveld, Pieter ;

Schuster, Michael W. ;

Stadtmauer, Edward A. ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Ben-Yehuda, Dina ;

Lonial, Sagar ;

Goldschmidt, Hartmut ;

Reece, Donna ;

Neuwirth, Rachel ;

Anderson, Kenneth C. ;

Richardson, Paul G. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4784-4790

[7] Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients [J].

Curtis, Jeffrey R. ;

Xie, Fenglong ;

Chen, Lang ;

Muntner, Paul ;

Grijalva, Carlos G. ;

Spettell, Claire ;

Fernandes, Joaquim ;

Mcmahan, Raechele M. ;

Baddley, John W. ;

Saag, Kenneth G. ;

Beukelman, Timothy ;

Delzell, Elizabeth .

ARTHRITIS CARE & RESEARCH, 2012, 64 (10) :1480-1489

[8] Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry [J].

Dreyer, Lene ;

Mellemkjaer, Lene ;

Andersen, Anne Rodgaard ;

Bennett, Philip ;

Poulsen, Uta Engling ;

Ellingsen, Torkell Juulsgaard ;

Hansen, Torben Hoiland ;

Jensen, Dorte Vendelbo ;

Linde, Louise ;

Lindegaard, Hanne Merete ;

Loft, Anne Gitte Rasmussen ;

Nordin, Henrik ;

Omerovic, Emina ;

Rasmussen, Claus ;

Schlemmer, Annette ;

Tarp, Ulrik ;

Hetland, Merete Lund .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (01) :79-82

[9] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].

Eichhorst, BF ;

Busch, R ;

Hopfinger, G ;

Pasold, R ;

Hensel, M ;

Steinbrecher, C ;

Siehl, S ;

Jäger, U ;

Bergmann, M ;

Stilgenbauer, S ;

Schweighofer, C ;

Wendtner, CM ;

Döhner, H ;

Brittinger, G ;

Emmerich, B ;

Hallek, M .

BLOOD, 2006, 107 (03) :885-891

[10] Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].

Gardam, MA ;

Keystone, EC ;

Menzies, R ;

Manners, S ;

Skamene, E ;

Long, R ;

Vinh, DC .

LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155

← 1 2 3 4 →